Prem Pavoor
Partner @ Eight Roads Ventures
Mumbai, India
Prem Pavoor is a Series B investor at Eight Roads Ventures in Mumbai focused on Health Care and Biotechnology. Prem is a Managing Director at FIL Capital Advisors (India) Private Limited, where he focuses on sectors that include life sciences, healthcare, speciality chemicals and agriculture. Prem brings a cumulative 14 years of experience in management consulting, engineering consulting and technology research, both in the United States and in India.Most recently, Prem was an Engagement Manager with McKinsey & Company’s Pharmaceutical and Medical Products Practice in New Jersey, where he advised pharmaceutical/biotech, consumer goods and private equity clients on areas that included R&D, business development, post-merger integrations and manufacturing.Prior to McKinsey, Prem served as an engineering consultant to the Mitsubishi Chemical Corporation in Japan and to a drug delivery company, Alkermes, Inc., in Boston, on design and scale-up of manufacturing processes.Prem’s doctoral thesis work, performed at the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (Boston), focused on enhancing the performance of medical implants. The work is the subject of several international peer-reviewed publications and a U.S. patent. Prem was awarded the 2004 MIT-OMNOVA award for Excellence in Polymer Research for his thesis contribution.Prem holds a Bachelors degree in Chemical Engineering from the Institute of Chemical Technology (formerly UDCT), Mumbai, a MS and Ph.D. in Chemical Engineering Practice from the Massachusetts Institute of Technology (MIT) and an MBA from MIT Sloan.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Prem Pavoor invests in
Stages Prem Pavoor invests in
Countries Prem Pavoor invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (50%)
- Biotechnology 4 (50%)
- Wellness 2 (25%)
- Pharmaceutical 2 (25%)
- CRM 1 (13%)
Stage
- Series B 2 (25%)
- Series C 2 (25%)
- Venture - Series Unknown 2 (25%)
- Series A 1 (13%)
- Funding Round 1 (13%)
Country
- India 4 (50%)
- United States 2 (25%)
- Trinidad and Tobago 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| They believe that the no one knows healthcare data better than the healthcare organizations that create it. However, healthcare organizations often lack the tools to generate insights from this data. Statisticians, data scientists and technology gurus can create tools, but these tools have no value until merged with the valuable domain knowledgethat only healthcare organizations possess. They empower healthcare organizations with data science tools to leverage their deep domain knowledge and generate novel insights from their data. | $39M / Series B / Mar 14, 2024 | ||
| Enko Chem discovers and develops novel products for farmers to protect their crops from pests and diseases. Their proprietary technology platform represents a revolutionary approach to rapidly discover safe and economical solutions that are needed to ensure sustainable food production.It was founded in 2017 and headquartered in Woburn,Massachusetts. | $10M / Series C / Jan 31, 2023 | ||
| Delivering cost effective biosimilars by developing disruptive technologies, advanced analytics and state-of-the-art manufacturing facility. Being the most desired Biotech company to work for by creating an unparalleled work culture. Broadening the footprint of their innovative technologies through strategic global alliances. | $50.3M / Venture - Series Unknown / Jan 30, 2023 | ||
| Spry is a cloud-based operating system that allows movement health professionals to collect and analyze patient data in real time. | $7M / Series A / Jun 22, 2022 | ||
| Toothsi is a dental company that offers clear aligners, an alternative to traditional braces, to gradually shift teeth into proper alignment. Toothsi's aligners are removable, invisible, and more comfortable than metal braces. Toothsi also provides oral hygiene products, teeth whitening solutions, and aligner accessories for complete oralcare. | $40M / Series C / May 02, 2022 | ||
| Toothsi is a dental company that offers clear aligners, an alternative to traditional braces, to gradually shift teeth into proper alignment. Toothsi's aligners are removable, invisible, and more comfortable than metal braces. Toothsi also provides oral hygiene products, teeth whitening solutions, and aligner accessories for complete oralcare. | $19.9M / Series B / Aug 06, 2021 | ||
| Caplin Point was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994 following its IPO which was oversubscribed 117 times, the proceeds of which were deployed in setting up a manufacturing facility at Pondicherry. Thereafter, the Company expanded its product range andincreased its production capacity. The Company focused on the emerging markets of Latin America, Caribbean, Francophone and Southern Africa and is today one of the leading suppliers of Pharmaceuticals in these regions, with over 2000 product licenses across the globe. The Company is entering into the Regulated Markets for Injectables through its state of the art manufacturing plant, capable of handling Liquid Injectables in Vials, Ampoules, Lyophilized Vials and Ophthalmic dosages. The facility is approved by US FDA, EU-GMP, ANVISA-Brazil and INVIMA-Colombia. | $30.6M / Venture - Series Unknown / Jan 18, 2019 | ||
| PlasmaGen BioSciences is an Indian Bio-pharmaceutical organization specializing exclusively in Plasma Protein Therapy.Headquartered in Bangalore- India, PlasmaGen has been making every effort in the domain of Plasma product Industry and has become an Imperative one stop destination for the medical fraternity for most of the plasma products need.They have a basket of plasma products and the widest range of immunoglobulins in India catering to the requisites of various realms viz. Haematology, Oncology, Immunology, Paediatrics, Rheumatology, Dermatology and Neurology. | $25M |
Co-Investors
About Eight Roads Ventures
Eight Roads Ventures is a global venture capital firm managing $11bn of assets across offices in the UK, China, India, Japan, and the US. Together with our associated funds, including our US sister fund F-Prime Capital, our 50-year history of investing includes partnerships with over 500 companies such as Alibaba, AppsFlyer, Chewy, Fareye, Fever,Flywire, Fireblocks, Funnel.io, Gloat, Hibob, Icertis, Neo4j, Otrium, Owkin, Paidy, Spendesk, Tibber, Toast, Wallapop and Xoom.
Eight Roads Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aditya Systla
Partner
|
|||
Gordon Zhang
Vice President & Principal
|
|||
Jarlon Tsang
Managing Partner, Head of China
|
|||
Michael Treskow
Partner
|
|||
|
Prem Pavoor
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Prem Pavoor invest in?
Prem Pavoor invests primarily in Health Care, Biotechnology and Wellness startups, most often at Series B and Series C stage. Most of the 8 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Prem Pavoor?
Public channels for Prem Pavoor include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Prem Pavoor last invest?
The most recent investment recorded for Prem Pavoor closed in Mar 2024. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
